Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nasser Hanna

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What Is New?Nasser Hanna
Journal of Oncology Practice|August 15, 2013
Helping patients quit tobacco: ASCO's efforts to help oncology care specialistsNasser Hanna
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 2, 2008
Unlocking the biological clues of lung cancerNasser Hanna
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?Nasser Hanna
BMJ (Clinical Research Ed.)|November 10, 2021
Advances in systemic therapy for non-small cell lung cancerMeagan Miller, Nasser Hanna
Hematology/Oncology Clinics of North America|December 4, 2016
Second-Line Chemotherapy and Beyond for Non-Small Cell Lung CancerGreg Durm, Nasser Hanna
Expert Opinion on Pharmacotherapy|March 7, 2014
Nintedanib for the treatment of non-small-cell lung cancerSawsan Rashdan, Nasser Hanna
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2020
The Case for Maintenance Pemetrexed Plus BevacizumabNasser Hanna, Shadia Jalal
Lung Cancer (Auckland, N.Z.)|July 8, 2021
Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung CancerNikhil Shukla, Nasser Hanna
Translational Lung Cancer Research|September 27, 2019
The shifting paradigm of biomarker-driven care in advanced non-small cell lung cancer (NSCLC)Greg Durm, Nasser Hanna
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What Is New?Nasser Hanna
Journal of Oncology Practice|August 15, 2013
Helping patients quit tobacco: ASCO's efforts to help oncology care specialistsNasser Hanna
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 2, 2008
Unlocking the biological clues of lung cancerNasser Hanna
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?Nasser Hanna
BMJ (Clinical Research Ed.)|November 10, 2021
Advances in systemic therapy for non-small cell lung cancerMeagan Miller, Nasser Hanna
Hematology/Oncology Clinics of North America|December 4, 2016
Second-Line Chemotherapy and Beyond for Non-Small Cell Lung CancerGreg Durm, Nasser Hanna
Expert Opinion on Pharmacotherapy|March 7, 2014
Nintedanib for the treatment of non-small-cell lung cancerSawsan Rashdan, Nasser Hanna
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2020
The Case for Maintenance Pemetrexed Plus BevacizumabNasser Hanna, Shadia Jalal
Lung Cancer (Auckland, N.Z.)|July 8, 2021
Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung CancerNikhil Shukla, Nasser Hanna
Translational Lung Cancer Research|September 27, 2019
The shifting paradigm of biomarker-driven care in advanced non-small cell lung cancer (NSCLC)Greg Durm, Nasser Hanna
Pageof 10